Fact checked by Nick Blackmer Clinical trials are a testing phase for drugs, devices, and procedures. These research studies ...

The Study presents a novel approach to improving the global applicability of clinical trial outcomes by assessing how well results from controlled trials translate to real-world patient populations.

A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

A pair of professional organizations in the U.K. is calling for the biopharma industry and national government to take action ...

New Ipsos data shows that while 58% of UK adults are willing to join clinical trials, this drops to 41% among ethnic minority ...

An analysis of key drug trials for psoriatic arthritis shows geographic disparities and racial gaps; most participants have ...

Black patients tend to experience more aggressive instances of MS and face greater barriers to diagnosis and treatment.

Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.

As stakeholders debate fair market value in clinical trial budgeting, a new task force works to align sponsors, CROs, and ...

Looking ahead, the BMC is poised to expand its reach, foster greater collaboration among stakeholders, and set new benchmarks ...

The UK government has set out a 10 Year Health Plan, promising to transform clinical trials and make the UK a scientific ...